Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Maija Hollmén|Clinical Cancer Research|2021Cited by 53